Alethio Funds G6B Antibody Development for Essential Thrombocythemia
Alethio Therapeutics closed a $90 million Series A on November 5 to advance ATX-011, a G6B-targeting antibody, from IND-enabling studies into Phase 1/2a testing in essential thrombocythemia. This Oxford spinout financing is new capital…
